tweenvest

TenNor Therapeutics (Suzhou) Limited (SEHK: 6872)

Salud · Biotecnología · CN

68,60 HK$

-1,44 % hoy · -67,5 % 1 año

Ficha pública
Un resumen gratuito de TenNor Therapeutics (Suzhou) Limited, con datos del 15 nov 2026. El análisis completo está en la app.Abrir en la app

TenNor Therapeutics (Suzhou) Limited (SEHK: 6872) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 457,56 M $ y tiene 56 empleados.

En los últimos doce meses la acción ha bajado un 67,5 % y ha cotizado entre 65,20 y 287,00.

Tweenvest puntúa a TenNor Therapeutics (Suzhou) Limited en cuatro factores: calidad 44/100, valor 100/100. Su punto más fuerte es valor.

Evolución de la cotización de 6872

22 may 2026 · 211,00Cierres semanales 66,00 – 264,8016 nov 2026 · 68,60

Cifras clave

Capitalización
457,56 M $
Ingresos (últ. 12 m)
—
PER
-16,89
BPA
-4,28
Rent. por dividendo
—
Beta (5 años)
—
Máximo 52 semanas
287,00 HK$
Mínimo 52 semanas
65,20 HK$
Volumen medio (3 m)
—
Acciones en circulación
52,33 M
Empleados
56
Próximos resultados
—

Sobre TenNor Therapeutics (Suzhou) Limited

TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.

ISIN
CNE100007KG6
Fundada en
2012
Cotiza desde
22 may 2026
Bolsa
The Stock Exchange of Hong Kong Ltd.
Divisa
HKD
EmpresaCapitalizaciónPrecioDía
MiMedx Group, Inc.NasdaqCM: MDXG464,04 M $3,18 $0,00 %
Thalys Medical Technology Group CorporationSHSE: 603716462,69 M $13,91 CN¥-2,59 %
Assembly Biosciences, Inc.NasdaqGS: ASMB460,74 M $22,50 $+5,68 %
HanchorBio Inc.TWSE: 7827458,12 M $108,00 NT$-9,62 %
Wuhan Hiteck Biological Pharma Co.,LtdSZSE: 300683456,90 M $23,30 CN¥+3,42 %
Ever Supreme Bio Technology Co., LtdTPEX: 6712452,94 M $148,00 NT$+1,72 %
Qurient Co., Ltd.KOSDAQ: A115180441,89 M $14.510,00 ₩-11,74 %
Qingdao Vland Biotech INC.SHSE: 603739440,25 M $11,60 CN¥+0,87 %

Ver todas las empresas de biotecnología →